Skip to main content
. Author manuscript; available in PMC: 2010 Apr 1.
Published in final edited form as: Clin Pharmacol Ther. 2007 Jul 4;83(2):300–306. doi: 10.1038/sj.clpt.6100282

Table 1.

Week-2 and -56 pharmacokinetic characteristics of efavirenz

Dose CL/F
AUC24 Cmin Cmax
Statistic (mg) (mg/kg) (mg/m2) (mg h/l) (mg/l) (mg/l) (l/h/kg) (l/h/m2)
Efavirenz, n=50
    Mean 310 12 318 76 2.09 4.73 0.21 5.51
    Median 275 12 317 60 1.45 4.09 0.19 5.37
    SD 102 1.4 14.4 58 2.16 2.76 0.09 2.42
    %CV 33 12 5 77 103.1 58.3 45.7 43.8
    Minimum 200 8 288 26 0.11 1.76 0.03 0.74
    Maximum 750 15 359 414 13.88 19.25 0.42 11.53
Efavirenz, n=34
    Mean 379 14 376 67 1.64 4.39 0.26 7.34
    Median 400 13 367 60 1.30 4.55 0.23 5.95
    SD 124 5 116 33 1.27 1.73 0.20 6.18
    %CV 33 36 31 59 77.3 39.5 74.3 84.1
    Minimum 50 3 69 9 BLQ 0.90 0.05 1.71
    Maximum 750 23 559 176 6.10 9.00 1.07 36.24

AUC24, area under the plasma concentration–time curve from time 0 to 24 h post-dose; BLQ, below the limit of quantitation; Cmin, minimum measured concentration; CL/F, apparent oral clearance; Cmax, observed maximum concentration; %CV, % coefficient of variation.